Gastrointestinal Dissolution and Absorption of Class II Drugs

Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability

Volumn 40, Issue , 2009, Pages 33-51

  Dahan, Arik S ^a   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Computational model; Gaussian process; Neural network; Solubility; Support vector machines

Indexed keywords

SOLUBILITY; SUPPORT VECTOR MACHINES;

CLASS II; COMPUTATIONAL MODEL; GAUSSIAN PROCESSES;

NEURAL NETWORKS;

EID: 84964637399     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623860.ch3     Document Type: Chapter

References (93)

1. Dahan, A. and Hoffman, A. (2006) Enhancement in Drug Delivery (eds E. Touitou and B.W. Barry), CRC Press, pp. 111-127.
2. Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46 (1-3), 3.
3. van de Waterbeemd, H., Smith, D.A., Beaumont, K. and Walker, D.K. (2001) Property-based design: optimization of drug absorption and pharmacokinetics. Journal of Medicinal Chemistry, 44 (9), 1313-1333.
4. Lennernas, H. (1998) Human intestinal permeability. Journal ofPharmaceutical Sciences, 87 (4), 403-410.
5. Yu, L.X., Lipka, E., Crison, J.R. and Amidon, G.L. (1996) Transportapproaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Advanced Drug Delivery Reviews, 19 (3), 359.
6. Amidon, G.L., Lennernas, H., Shah, V.P. and Crison, J.R. (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12 (3), 413.
7. Oh, D.M., Curl, R.L. and Amidon, G.L. (1993) Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharmaceutical Research, 10 (2), 264.
8. Sinko, P.J., Leesman, G.D. and Amidon, G.L. (1991) Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharmaceutical Research, 8 (8), 979.
9. Becker, C., Dressman, J.B., Amidon, G.L., Junginger, H.E., Kopp, S., Midha, K.K., Shah, V.P., Stavchansky, S. and Barends, D.M. (2008) Biowaiver monographs for immediate release solid oral dosage forms: pyrazinamide. Journal of Pharmaceutical Sciences, 97 (9), 3709-3720.
10. Blume, H.H. and Schug, B.S. (1999) The biopharmaceutics classification system (BCS): Class III drugs - better candidates for BA/BE waiver? European Journal of Pharmaceutical Sciences, 9 (2), 117.
11. Cheng, C.L., Yu, L.X., Lee, H.L., Yang, C.Y., Lue, C.S. and Chou, C.H. (2004) Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences, 22 (4), 297.
12. Jantratid, E., Prakongpan, S., Amidon, G.L. and Dressman, J. (2006) Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clinical Pharmacokinetics, 45 (4), 385-399.
13. Kasim, N.A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A.S., Junginger, H.E., Stavchansky, S.A., Midha, K.K., Shah, V.P. and Amidon, G.L. (2004) Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Molecular Pharmaceutics, 1 (1), 85-96.
14. Lindenberg, M., Kopp, S. and Dressman, J.B. (2004) Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutical Sciences, 58 (2), 265.
15. Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L.X. and Amidon, G.L. (2006) A provisional biopharmaceutical classification ofthe top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Molecular Pharmaceutics, 3 (6), 631-643.
16. Yang, Y., Faustino, P.J., Volpe, D.A., Ellison, C.D., Lyon, R.C. and Yu, L.X. (2007) Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Molecular Pharmaceutics, 4 (4), 608-614.
17. Lobenberg, R. and Amidon, G.L. (2000) Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics, 50 (1), 3-12.
18. Martinez, M.N. and Amidon, G.L. (2002)A mechanistic approach to understanding the factors affecting drug absorption: a review offundamentals. Journal ofClinical Pharmacology, 42 (6), 620-643.
19. Dressman, J. and Fleisher, D. (1986) Mixing-tank model for predicting dissolution rate control or oral absorption. Journal of Pharmaceutical Sciences, 75 (2), 109-116.
20. Jounela, A., Pentikainen, P. and Sothmann, A. (1975) Effect ofparticle size on the bioavailability of digoxin. European Journal of Clinical Pharmacology, 8 (5), 365-370.
21. Crison, J.R., Weiner, N.D. and Amidon, G.L. (1997) Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. Journal ofPharmaceutical Sciences, 86 (3), 384-388.
22. Shah, V.P., Konecny, J.J., Everett, R.L., McCullough, B., Noorizadeh, A.C. and Skelly, J.P. (1989) In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharmaceutical Research, 6 (7), 612.
23. Dressman, J.B., Amidon, G.L., Reppas, C. and Shah, V.P. (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharmaceutical Research, 15 (1), 11.
24. Fagerholm, U. (2007) Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS). The Journal of Pharmacy and Pharmacology, 59, 751.
25. Wilding, I. (1999) Evolution of the biopharmaceutics classification system (BCS) to oral modified release (MR) formulations; what do we need to consider? European Journal of Pharmaceutical Sciences, 8 (3), 157-159.
26. Levich, V. (1962) Physicochemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ.
27. Nernst, W. and Brunner, E. (1904) Theorie der reaktionsgeschwindigkeit in heterogenen systemen. Zeitschrift für Physikalische Chemie, 47, 52-110.
28. Noyes, A. and Whitney, W. (1897) The rate ofsolution ofsolid substances in their own solutions. Journal ofthe American Chemical Society, 19, 930-934.
29. Bakatselou, V., Oppenheim, R.C. and Dressman, J.B. (1991) Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharmaceutical Research, 8 (12), 14-61.
30. Sheng, J.J. (2007) Toward an in vitro bioequivalence test. PhD Thesis, University of Michigan, Ann Arbor.
31. Persson, E., Gustafsson, A.-S., Carlsson, A., Nilsson, R., Knutson, L., Forsell, P., Hanisch, G., Lennernas, H. and Abrahamsson, B. (2005) The effects offood on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharmaceutical Research, 22 (12), 2141.
32. Porter, C.J.H., Trevaskis, N.L. and Charman, W.N. (2007) Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Reviews. Drug Discovery, 6 (3), 231.
33. Amidon, G.E., Higuchi, W. and Ho, N. (1982) Theoretical and experimental studies of transport of micelle-solubilized solutes. Journal of Pharmaceutical Sciences, 71 (1), 77-84.
34. Granero, G., Ramachandran, C. and Amidon, G.L. (2005) Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Development and Industrial Pharmacy, 31 (9), 917-922.
35. Horter, D. and Dressman, J.B. (2001) Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews, 46 (1-3), 75.
36. Luner, P.E. (2000) Wetting properties of bile salt solutions and dissolution media. Journal of Pharmaceutical Sciences, 89 (3), 382-395.
37. Luner, P.E. and Kamp, D.V. (2001) Wetting behavior of bile salt-lipid dispersions and dissolution media patterned after intestinal fluids. Journal ofPharmaceutical Sciences, 90 (3), 348-359.
38. Sheng, J.J., Kasim, N.A., Chandrasekharan, R. and Amidon, G.L. (2006) Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. European Journal ofPharmaceutical Sciences, 29 (3-4), 306.
39. Balakrishnan, A., Rege, B.D., Amidon, G.L. and Polli, J.E. (2004) Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. Journal of Pharmaceutical Sciences, 93 (8), 2064-2075.
40. Davis, S.S., Hardy, J.G. and Fara, J.W. (1986) Transit of pharmaceutical dosage forms through the small intestine. Gut, 27 (8), 886-892.
41. Lindahl, A., Ungell, A.L., Knutson, L. and Lennernäs, H. (1997) Characterization of fluids from the stomach and proximal jejunum in men and women. Pharmaceutical Research, 14 (4), 497.
42. Oberle, R. and Amidon, G.L. (1987) The influence ofvariable gastric emptying and intestinal transit rates on the plasma level curve ofcimetidine: an explanation for the double peak phenomenon. Journal of Pharmacokinetics and Biopharmaceutics, 15 (5), 529-544.
43. Kalantzi, L., Goumas, K., Kalioras, V., Abrahamsson, B., Dressman, J. and Reppas, C. (2006) Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability /bioequivalence studies. Pharmaceutical Research, 23 (1), 165.
44. Galia, E., Nicolaides, E., Hörter, D., Löbenberg, R., Reppas, C. and Dressman, J.B. (1998) Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharmaceutical Research, 15 (5), 698.
45. Kalantzi, L., Persson, E., Polentarutti, B., Abrahamsson, B., Goumas, K., Dressman, J. and Reppas, C. (2006) Canine intestinal contents vs. simulated media for the assessment ofsolubility oftwo weak bases in the human small intestinal contents. Pharmaceutical Research, 23 (6), 1373.
46. Russell, T.L., Berardi, R.R., Barnett, J.L., O'Sullivan, T.L., Wagner, J.G. and Dressman, J.B. (1994) pH-related changes in the absorption of dipyridamole in the elderly. Pharmaceutical Research, 11 (1), 136.
47. Zhou, R., Moench, P., Heran, C., Lu, X., Mathias, N., Faria, T.N., Wall, D.A., Hussain, M.A., Smith, R.L. and Sun, D. (2005) pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharmaceutical Research, 22 (2), 188.
48. Granero, G., Ramachandran, C. and Amidon, G.L. (2006) Rapid in vivo dissolution ofketoprofen: implications on the biopharmaceutics classification system. Pharmazie, 61 (8), 673-676.
49. Jinno, J., Oh, D.M., Crison, J.R. and Amidon, G.L. (2000) Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. Journal of Pharmaceutical Sciences, 89 (2), 268-274.
50. Langguth, P., Lee, K., Spahn-Langguth, H. and Amidon, G.L. (1994) Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharmaceutics & Drug Disposition, 15 (9), 719-746.
51. Yu, L.X. and Amidon, G.L. (1999) A compartmental absorption and transit model for estimating oral drug absorption. International Journal ofPharmaceutics, 186 (2), 119.
52. Yu, L.X., Crison, J.R. and Amidon, G.L. (1996) Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. International Journal of Pharmaceutics, 140 (1), 111.
53. Dressman, J.B., Vertzoni, M., Goumas, K. and Reppas, C. (2007) Estimating drug solubility in the gastrointestinal tract. Advanced DrugDelivery Reviews, 59 (7), 591.
54. Lobenberg, R., Kramer, J., Shah, V.P., Amidon, G.L. and Dressman, J.B. (2000) Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior ofglibenclamide. Pharmaceutical Research, 17 (4), 439.
55. Sinko, C.M., Yee, A.F. and Amidon, G.L. (1990) The effect of physical aging on the dissolution rate ofanionic polyelectrolytes. Pharmaceutical Research, 7 (6), 648.
56. Aungst, B.J., Nguyen, N.H., Taylor, N.J. and Bindra, D.S. (2002) Formulation and food effects on the oral absorption of a poorly water soluble, highly permeable antiretroviral agent. Journal of Pharmaceutical Sciences, 91 (6), 1390-1395.
57. Bonlokke, L., Hovgaard, L., Kristensen, H.G., Knutson, L. and Lennernoäs, H. (2001) Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut(R)) in humans. European Journal of Pharmaceutical Sciences, 12 (3), 239.
58. Kostewicz, E.S., Brauns, U., Becker, R. and Dressman, J.B. (2002) Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharmaceutical Research, 19 (3), 345.
59. Takano, R., Sugano, K., Higashida, A., Hayashi, Y., Machida, M., Aso, Y. and Yamashita, S. (2006) Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharmaceutical Research, 23 (6), 1144.
60. Custodio, J.M., Wu, C.Y. and Benet, L.Z. (2008) Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Advanced Drug Delivery Reviews, 60 (6), 717.
61. Dressman, J.B. and Reppas, C. (2000) In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. European Journal of Pharmaceutical Sciences, 11 (Suppl. 2), S73.
62. Fordtran, J. and Locklear, T. (1966) Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. The American Journal ofDigestive Diseases, 11 (7), 503-521.
63. Macheras, P., Koupparis, M. and Tsaprounis, C. (1986) Drug dissolution studies in milk using the automated flow injection serial dynamic dialysis technique. International Journal of Pharmaceutics, 33 (1-3), 125.
64. Galia, E., Horton, J. and Dressman, J.B. (1999) Albendazole generics-a comparative in vitro study. Pharmaceutical Research, 16 (12), 1871.
65. Nicolaides, E., Symillides, M., Dressman, J.B. and Reppas, C. (2001) Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharmaceutical Research, 18 (3), 380.
66. Vertzoni, M., Dressman, J., Butler, J., Hempenstall, J. and Reppas, C. (2005) Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. European Journal of Pharmaceutics and Biopharmaceutics, 60 (3), 413.
67. Scholz, A., Abrahamsson, B., Diebold, S.M., Kostewicz, E., Polentarutti, B.I., Ungell, A.-L. and Dressman, J.B. (2002) Influence of hydrodynamics and particle size on the absorption of felodipine in labradors. Pharmaceutical Research, 19 (1), 42.
68. Scholz, A., Kostewicz, E.,Abrahamsson, B. and Dressman, J.B. (2003) Can the USP paddle method be used to represent in-vivo hydrodynamics? The Journal of Pharmacy and Pharmacology, 55, 443.
69. Sheng, J.J., Sirois, P.J., Dressman, J.B. and Amidon, G.L. (2008) Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed. Journal of Pharmaceutical Sciences, in press.
70. Charman, W.N. (2000) Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. Journal of Pharmaceutical Sciences, 89 (8), 967-978.
71. Gershanik, T. and Benita, S. (2000) Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. European Journal of Pharmaceutics and Biopharmaceutics, 50 (1), 179-188.
72. Fleisher, D., Li, C., Zhou, Y., Pao, L.H. and Karim, A. (1999) Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clinical Pharmacokinetics, 36 (3), 233-254.
73. Dintaman, J.M. and Silverman, J.A. (1999) Inhibition of P-glycoprotein by D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharmaceutical Research, 16 (10), 1550.
74. Nerurkar, M.M., Burton, P.S. and Borchardt, R.T. (1996) The use of surfactants to enhance the permeability of peptides through Caco-2 cells byinhibition of an apically polarized efflux system. Pharmaceutical Research, 13 (4), 528.
75. Dahan, A. and Hoffman, A. (2005) Evaluation ofa chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. European Journal of Pharmaceutical Sciences, 24 (4), 381-388.
76. Gershkovich, P. and Hoffman, A. (2007) Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. European Journal of Pharmaceutical Sciences, 32 (1), 24.
77. Tso, P. (1985) Gastrointestinal digestion and absorption of lipid. Advances in Lipid Research, 21, 143-186.
78. Dahan, A. and Hoffman, A. (2008) Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. Journal ofControlled Release, 129 (1), 1-10.
79. Porter, C.J.H. and Charman, W.N. (2001) In vitro assessment of oral lipid based formulations. Advanced Drug Delivery Reviews, 50 (Suppl. 1), S127.
80. Sek, L., Porter, C.J.H., Kaukonen, A.M. and Charman, W.N. (2002) Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. The Journal of Pharmacy and Pharmacology, 54, 29.
81. Zangenberg, N.H., Mullertz, A., Gjelstrup Kristensen, H. and Hovgaard, L. (2001) A dynamic in vitro lipolysis model. II. Evaluation of the model. European Journal of Pharmaceutical Sciences, 14 (3), 237.
82. Porter, C.J.H., Kaukonen, A.M., Taillardat-Bertschinger, A., Boyd, B.J., O'Connor, J.M., Edwards, G.A. and Charman, W.N. (2004) Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. Journal of Pharmaceutical Sciences, 93 (5), 1110-1121.
83. Dahan, A. and Hoffman, A. (2007) The effect ofdifferent lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. European Journal of Pharmaceutics and Biopharmaceutics, 67 (1), 96.
84. Dahan, A. and Hoffman, A. (2006) Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharmaceutical Research, 23 (9), 2165-2174.
85. Lennernäs, H. and Abrahamsson, B. (2005) The use ofbiopharmaceutic classification of drugs in drug discovery and development: current status and future extension. The Journal of Pharmacy and Pharmacology, 57, 273.
86. Polli, J.E., Yu, L.X., Cook, J.A., Amidon, G. L., Borchardt, R.T., Burnside, B.A., Burton, P.S., Chen, M.-L., Conner, D.P., Faustino, P.J., Hawi, A.A., Hussain, A.S., Joshi, H.N., Kwei, G., Lee, V.H.L., Lesko, L.J., Lipper, R.A., Loper, A.E., Nerurkar, S.G., Polli, J.W., Sanvordeker, D.R., Taneja, R., Uppoor, R.S., Vattikonda, C.S., Wilding, I. and Zhang, G. (2004) Summary workshop report: biopharmaceutics classification system-implementation challenges and extension opportunities. Journal of Pharmaceutical Sciences, 936 1375-1381.
87. Rinaki, E., Dokoumetzidis, A., Valsami, G. and Macheras, P. (2004) Identification of biowaivers among class II drugs: theoretical justification and practical examples. Pharmaceutical Research, 21 (9), 1567.
88. Yu, L.X., Amidon, G.L., Polli, J.E., Zhao, H. , Mehta, M.U., Conner, D.P., Shah, V.P., Lesko, L.J., Chen, M.L., Lee, V.H.L. and Hussain, A.S. (2002) Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research, 19 (7), 921.
89. Youngberg, C., Berardi, R., Howatt, W., Hyneck, M., Amidon, G., Meyer, J. and Dressman, J. (1987) Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Digestive Diseases and Sciences, 32 (5), 472-480.
90. Kaus, L.C., Gillespie, W.R., Hussain, A.S. and Amidon, G.L. (1999) The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharmaceutical Research, 16 (2), 272.
91. Dressman, J. (1997) Scientific Foundations for Regulating Drug Product Quality (eds G.L. Amidon, J. Robinson and R. Williams), AAPS Press, pp. 155-168.
92. Yazdanian, M., Briggs, K., Jankovsky, C. and Hawi, A. (2004) The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharmaceutical Research, 21 (2), 293.
93. Lipka, E. and Amidon, G.L. (1999) Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. Journal ofControlled Release, 62 (1-2), 41.